• GBC set a Buy rating on Bio-Gate, setting a EUR 3.4 price target for Dec. 31, 2027.
• 2025 revenue rose 4.9% to EUR 7.4 million; EBITDA loss narrowed to EUR 0.9 million from EUR 1.3 million.
• GBC forecast revenue of EUR 7.4 million in 2026, rising to EUR 8 million in 2027, with faster growth projected in 2028.
• Profitability path seen improving, with EBITDA projected at EUR -0.3 million in 2026, EUR -0.2 million in 2027, EUR 0.35 million in 2028.
• GBC flagged a 5-for-1 share consolidation plan, noting its valuation excludes potential dilution from a planned cash capital increase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Gate AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26190) on July 16, 2026, and is solely responsible for the information contained therein.